Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 13 March 2020, 08:09 HKT/SGT

Source: Mitsubishi Corporation
Mitsubishi Corporation: Establishment of PeptiGrowth Inc. for Development and Commercialization of Peptide Alternatives to Growth Factors for Cell Culture

TOKYO, Mar 13, 2020 - (JCN Newswire) - Mitsubishi Corporation (MC) and PeptiDream Inc. have agreed to establish a joint venture company that will develop, produce and sell peptide(1) alternatives to growth factors, key ingredients of cell culture(2) used in the manufacturing of cell therapy, regenerative medicines and other biopharmaceuticals.

The joint venture, PeptiGrowth Inc. (PeptiGrowth), will be owned 60.5% by MC and 39.5% by PeptiDream. The Company will leverage expertise and know-hows of both parent companies to work towards the advancement of cell therapy, regenerative medicines and other biopharmaceuticals in the pharmaceutical industry.

Growth factors are a class of proteins that are widely present in humans and other animals. In addition to playing an important role in cell growth and proliferation, it is crucially involved in induction of differentiation of stem cells (iPS cells, ES cells, etc.) into nerve, blood, and other types of cells. Currently, growth factors are mainly extracted from animal serum or produced by gene recombination technology, however, their production presents a number of challenges to the pharmaceutical industry, including safety risks due to contamination with impurities, variation in quality among production lots, and high production costs.

PeptiGrowth will utilize PeptiDream's proprietary drug discovery platform system, PDPS (Peptide Discovery Platform System), to identify alternative peptides that perform the equivalent function as growth factors, and develop a new chemical synthesis method that does not use animal serum or gene recombination technology. In addition, by establishing a commercial manufacturing process and system, PeptiGrowth will achieve high purity, less variation among production lots in terms of specification and quality, with lower costs. Dozens of growth factors have been identified to date, and in order to realize a completely Xeno-Free culture medium*3, multiple growth factors need to be replaced with chemically synthesized alternative compounds. This is a world-first in terms of the comprehensive development of chemically synthesized, peptide alternatives to multiple growth factors, and both MC and PeptiDream believe such an initiative to realize the peptide alternatives to multiple growth factors is essential for further advancement of cell therapy and regenerative medicines in the industry.

MC will assign officers for key management positions, including the CEO of PeptiGrowth. The new company will fully leverage the advantage of the MC Group's global network and its broad customer base to enhance marketing and sales functions, which will lead to a faster growth of alternative peptides market globally. This will also help to address challenges of the industry and contribute to further advancement of cell therapy and regenerative medicines.

(1) Short chains of approximately 50 or fewer amino acids and linked by peptide bonds.
(2) A liquid or solid that contains the nutrients needed to grow cells outside the body. It is mainly composed of growth factors, amino acids, sugars, and minerals.
(3) Optimal medium for cell growth and proliferation, devoid of animal except human-derived components

Mitsubishi Corporation

PeptiDream Inc.

Topic: Press release summary
Sectors: Healthcare & Pharm
From the Asia Corporate News Network

Copyright © 2021 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Mitsubishi Corporation Links

Mitsubishi Corporation
Jan 19, 2021 09:25 HKT/SGT
Mitsubishi Corporation: Commercial Operations Commence at Methanol / Dimethyl Ether Plant in Trinidad and Tobago
Dec 24, 2020 16:01 HKT/SGT
Vietnam Pilot Project Utilizing TradeWaltz Platform Adopted Under Government's Supply-Chain Diversification Scheme
Dec 8, 2020 15:01 HKT/SGT
MC Signs Rolling Stock Contracts with Myanma Railways
Nov 24, 2020 13:15 HKT/SGT
Mitsubishi Corporation Signs Contract with Egyptian Government for Phase 1 of Cairo Metro Line 4
Oct 30, 2020 23:10 HKT/SGT
Hitachi Rail and Mitsubishi Corp to Deliver Metro de Panama Line 3 worth JPY 92.0 Billion
Oct 28, 2020 09:30 HKT/SGT
Trials of Jointly Developed Compact LNG Filling System to Commence in Hokkaido
Oct 27, 2020 11:25 HKT/SGT
Mitsubishi Corporation: Cross-Industry Investment by Seven Enterprises in New TradeWaltz Platform
Oct 1, 2020 09:09 HKT/SGT
MC Commences Feasibility Study on Biometric Authentication Platform in Turkey
Sept 23, 2020 15:00 HKT/SGT
Mitsubishi Corporation: Use of CO2 in Concrete / Partnership with Blue Planet Systems Corporation
Sept 15, 2020 08:41 HKT/SGT
Mitsubishi Corporation and Surbana Jurong Joint Venture to Form Partnership with SinarMas Land to Advance Smart, Sustainable Transit-Oriented Developments in Indonesia
More news >>
 News Alerts
Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6859 8575

Connect With us: